Novartis gets FDA RMAT designation for Kymriah in follicular lymphoma
Follicular lymphoma, which is said to be the second most common form of non-Hodgkins lymphoma (NHL), is an indolent lymphoma and represents around 22% of NHL cases. Claimed
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
Demand for these products, including Midazolam, Cisatracurium, and Rocuronium, has skyrocketed as a result of the global coronavirus pandemic. “For more than 30 years we have invested in
The trial dubbed CheckMate -743 saw the Opdivo, Yervoy combination delivered a statistically significant and clinically meaningful improvement in overall survival (OS) compared to chemotherapy comprised of pemetrexed
The study is expected to enroll approximately 270 patients across countries with high numbers of diagnosed cases, beginning in May, and will evaluate the impact of ULTOMIRIS, a